Synonyms: CDP 771 | CMA 676 | hP67.6-calicheamicin | Mylotarg® | WAY-CMA 676
gemtuzumab ozogamicin is an approved drug (FDA (2000), EMA (2018))
Compound class:
Antibody
Comment: This drug is an antibody-drug conjugate (ADC) that targets delivery of the highly cytotoxic ozogamicin (a derivative of calicheamicin γ1) to CD33 +ve myeloid cells [1].
|
Immunopharmacology Comments |
Gemtuzumab ozogamicin is an immune checkpoint modulator that delivers a toxic payload to target cancer cells. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Acute myeloid leukemia |
Disease Ontology:
DOID:9119 OMIM: 601626 Orphanet: ORPHA519 |
Approved in particular for CD33-positive AML. However, note that use in this indication has been withdrawn in some jurisdictions due to safety concerns and lack of significant efficacy. |